The short version of ACTH(4-10) fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
Semax 是一种人工合成的七肽，氨基酸序列为 Met-Glu-His-Phe-Pro-Gly-Pro，单字母缩写记作 MEHFPGP。它被归类为促肾上腺皮质激素片段 ACTH(4-10) 的结构类似物，但并不天然存在于生物体内。母体片段 ACTH(4-10) 的序列为 Met-Glu-His-Phe-Arg-Trp-Gly，Semax 替换了中间两个残基，并在羧基端延长了 Pro-Gly-Pro 三肽。这种延长被普遍认为能提升分子对肽酶的耐受性。
该化合物于二十世纪八十年代在俄罗斯被开发，相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性，而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示，这一方向促成了多个相关短肽的合成与筛选，而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Clinical evidence consists largely of small trials with modest sample sizes, often without independent replication. Reported endpoints include cognitive scores, recovery after stroke, and visual function, but study designs vary widely and few trials meet contemporary reporting standards. Systematic reviewers have noted a high risk of bias in several of these reports. No large multicenter trial conducted outside Russia has been published. The compound is therefore best described as investigational in most jurisdictions, with its clinical role still unresolved.
| Property | Value | Notes |
|---|---|---|
| 化学类别 | 合成七肽 | ACTH(4-10) 结构类似物 |
| 氨基酸序列 | Met-Glu-His-Phe-Pro-Gly-Pro | 单字母写作 MEHFPGP |
| 分子量 | 约 813.9 Da | 随确切形式和盐型略有变化 |
| 常见同义词 | ACTH(4-10) 类似物 | 俄语文献称 Семакс |
| 开发来源 | 俄罗斯 | 二十世纪八十年代 |
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
The research was continued by Lehmann who started a systematic study, first of cholesteryl benzoate, and then of related compounds which exhibited the double-melting phenomenon. He was able to make observations in polarized light, and his microscope was equipped with a hot stage (sample holder equipped with a heater) enabling high temperature observations. The intermediate cloudy phase clearly sustained flow, but other features, particularly the signature under a microscope, convinced Lehmann that he was dealing with a solid. By the end of August 1889 he had published his results. Lehmann's paper prompted work by Ludwig Gattermann who in 1890 published a paper on the synthesis of azoxyphenol ethers, such as para-azoxyanisole, which exhibited the same double-melting behaviour. Lehmann's interpretation of his results was controversial, and was not accepted by Gustav Heinrich Tammann, Georg Hermann Quincke, and Walther Nernst. In 1905 research by Rudolf Schenck addressed and largely resolved the objections of Tamman, Quincke and Nernst. Lehmann's work was continued and significantly expanded by the German chemist Daniel Vorländer who from the beginning of the 20th century had synthesized most of the liquid crystals known. In 1910–1922 research on liquid crystals, led by Georges Friedel, was carried on in France. In the period before X-rays liquid crystals were seen as merely a curiosity by scientists, and the field did not yield applications until the second half of the 20th century.
The 25 April 1953 issue of the journal Nature published a series of five articles giving the Watson and Crick double-helix structure DNA and evidence supporting it. The structure was reported in a letter in which they stated, "It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material." This letter was followed by a letter from Franklin and Gosling, which was the first publication of their own X-ray diffraction data and of their original analysis method. Then followed a letter by Wilkins and two of his colleagues, which contained an analysis of in vivo B-DNA X-ray patterns, and which supported the presence in vivo of the Watson and Crick structure. In April 2023, scientists, based on new evidence, concluded that Rosalind Franklin was a contributor and "equal player" in the discovery process of DNA, rather than otherwise, as may have been presented subsequently after the time of the discovery. In 1962, after Franklin's death, Watson, Crick, and Wilkins jointly received the Nobel Prize in Physiology or Medicine. Nobel Prizes are awarded only to living recipients. A debate continues about who should receive credit for the discovery. In an influential presentation in 1957, Crick laid out the central dogma of molecular biology, which foretold the relationship between DNA, RNA, and proteins, and articulated the "adaptor hypothesis". Final confirmation of the replication mechanism that was implied by the double-helical structure followed in 1958 through the Meselson–Stahl experiment.
Genetically modified foods are foods produced from organisms that have had specific changes introduced into their DNA with the methods of genetic engineering. These techniques have allowed for the introduction of new crop traits as well as a far greater control over a food's genetic structure than previously afforded by methods such as selective breeding and mutation breeding. Commercial sale of genetically modified foods began in 1994, when Calgene first marketed its Flavr Savr delayed ripening tomato. To date most genetic modification of foods have primarily focused on cash crops in high demand by farmers such as soybean, corn, canola, and cotton seed oil. These have been engineered for resistance to pathogens and herbicides and better nutrient profiles. GM livestock have also been experimentally developed; in November 2013 none were available on the market, but in 2015 the FDA approved the first GM salmon for commercial production and consumption. There is a scientific consensus that currently available food derived from GM crops poses no greater risk to human health than conventional food, but that each GM food needs to be tested on a case-by-case basis before introduction. Nonetheless, members of the public are much less likely than scientists to perceive GM foods as safe. The legal and regulatory status of GM foods varies by country, with some nations banning or restricting them, and others permitting them with widely differing degrees of regulation. GM crops also provide a number of ecological benefits, if not used in excess.
Sources: en.wikipedia.org
However, after Owen Hart accidentally injured Austin's neck in 1997, Austin changed his style from technical to brawler. His most famous finishing move is the Stone Cold Stunner, and he credits Michael Hayes with introducing the move to him. Following his retirement, he gave permission to Kevin Owens to use the move as his own finisher, but both have downplayed comparisons between the two. During his time as The Ringmaster, he used the Million Dollar Dream as a finishing move since it was Ted DiBiase's finisher. During his time in WCW, Austin used the Stun Gun (a move innovated by Eddie Gilbert as the Hot Shot) and the Hollywood & Vine (a standing modified figure-four leglock) as his finishers. Sporting a bald head and goatee, coupled with his ring attire which consisted of plain black trunks and boots, Austin relied solely on his personality to become popular. As "Stone Cold", Austin was portrayed on-screen as an anti-authority rebel who would consistently cuss and defy the company rules and guidelines of WWE Chairman Vince McMahon. One of Austin's taunts during the Attitude Era was to show the middle finger. To complement his persona, Austin was the recipient of two additional nicknames, commentator and real life friend Jim Ross dubbed him "The Texas Rattlesnake" due to the character's "...mannerisms, the motivation, the mindset, you can't trust this son of a bitch", while Austin later named himself "The Bionic Redneck" on account of the injuries he had suffered to his arms, neck and knees.
CO2 + NH3 + H2O → (NH4)HCO3 Since ammonium bicarbonate is thermally unstable, the reaction solution is kept cold, which allows the precipitation of the product as white solid. About 100,000 tons were produced in this way in 1997. Ammonia gas passed into a strong aqueous solution of the sesquicarbonate (a 2:1:1 mixture of (NH4)HCO3, (NH4)2CO3, and H2O) converts it into normal ammonium carbonate ((NH4)2CO3), which can be obtained in the crystalline condition from a solution prepared at about 30 °C. This compound on exposure to air gives off ammonia and reverts to ammonium bicarbonate.
=== EC 2.6.1: Transaminases === EC 2.6.1.1: aspartate transaminase EC 2.6.1.2: alanine transaminase EC 2.6.1.3: cysteine transaminase EC 2.6.1.4: glycine transaminase EC 2.6.1.5: tyrosine transaminase EC 2.6.1.6: leucine transaminase EC 2.6.1.7: kynurenine—oxoglutarate transaminase EC 2.6.1.8: deleted EC 2.6.1.9: histidinol-phosphate transaminase EC 2.6.1.10: deleted, included with EC 2.6.1.21, D-amino-acid transaminase EC 2.6.1.11: acetylornithine transaminase EC 2.6.1.12: alanine—oxo-acid transaminase EC 2.6.1.13: ornithine aminotransferase EC 2.6.1.14: asparagine—oxo-acid transaminase EC 2.6.1.15: glutamine—pyruvate transaminase EC 2.6.1.16: glutamine—fructose-6-phosphate transaminase (isomerizing) EC 2.6.1.17: succinyldiaminopimelate transaminase EC 2.6.1.18: β-alanine—pyruvate transaminase EC 2.6.1.19: 4-aminobutyrate transaminase EC 2.6.1.20: deleted EC 2.6.1.21: D-amino-acid transaminase EC 2.6.1.22: (S)-3-amino-2-methylpropionate transaminase EC 2.6.1.23: 4-hydroxyglutamate transaminase EC 2.6.1.24: diiodotyrosine transaminase EC 2.6.1.25: deleted, Now included with EC 2.6.1.24 diiodotyrosine transaminase EC 2.6.1.26: thyroid-hormone transaminase EC 2.6.1.27: tryptophan transaminase EC 2.6.1.28: tryptophan—phenylpyruvate transaminase EC 2.6.1.29: diamine transaminase EC 2.6.1.30: pyridoxamine—pyruvate transaminase EC 2.6.1.31: pyridoxamine—oxaloacetate transaminase EC 2.6.1.32: valine—3-methyl-2-oxovalerate transaminase EC 2.6.1.33: dTDP-4-amino-4,6-dideoxy-D-glucose transaminase EC 2.6.1.34: UDP-N-acetylbacillosamine transaminase EC 2.6.1.35: glycine—oxaloacetate transaminase EC 2.6.1.36: L-lysine 6-transaminase EC 2.6.1.37: (2-aminoethyl)phosphonate—pyruvate transaminase EC 2.6.1.38: histidine transaminase EC 2.6.1.39: 2-aminoadipate transaminase EC 2.6.1.40: (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.41: D-methionine—pyruvate transaminase EC 2.6.1.42: branched-chain-amino-acid transaminase EC 2.6.1.43: aminolevulinate transaminase EC 2.6.1.44: alanine—glyoxylate transaminase EC 2.6.1.45: serine—glyoxylate transaminase EC 2.6.1.46: diaminobutyrate—pyruvate transaminase EC 2.6.1.47: alanine—oxomalonate transaminase EC 2.6.1.48: 5-aminovalerate transaminase EC 2.6.1.49: dihydroxyphenylalanine transaminase EC 2.6.1.50: glutamine—scyllo-inositol transaminase EC 2.6.1.51: serine—pyruvate transaminase EC 2.6.1.52: phosphoserine transaminase EC 2.6.1.53: Now EC 1.4.1.13, glutamate synthase (NADPH) EC 2.6.1.54: pyridoxamine-phosphate transaminase EC 2.6.1.55: taurine—2-oxoglutarate transaminase EC 2.6.1.56: 1D-1-guanidino-3-amino-1,3-dideoxy-scyllo-inositol transaminase EC 2.6.1.57: aromatic-amino-acid transaminase EC 2.6.1.58: phenylalanine(histidine) transaminase EC 2.6.1.59: dTDP-4-amino-4,6-dideoxygalactose transaminase EC 2.6.1.60: aromatic-amino-acid—glyoxylate transaminase EC 2.6.1.61: identical to EC 2.6.1.40, (R)-3-amino-2-methylpropionate—pyruvate transaminase EC 2.6.1.62: adenosylmethionine—8-amino-7-oxononanoate transaminase EC 2.6.1.63: kynurenine—glyoxylate transaminase EC 2.6.1.64: glutamine—phenylpyruvate transaminase EC 2.6.1.65: N6-acetyl-β-lysine transaminase EC 2.6.1.66: valine—pyruvate transaminase EC 2.6.1.67: 2-aminohexanoate transaminase EC 2.6.1.68: Now classified as EC 2.6.1.13, ornithine aminotransferase and EC 2.6.1.36, L-lysine 6-transaminase EC 2.6.1.69: identical to EC 2.6.1.11, ((acetylornithine transaminase))|identical to EC 2.6.1.11, acetylornithine transaminase EC 2.6.1.70: aspartate—phenylpyruvate transaminase EC 2.6.1.71: lysine—pyruvate 6-transaminase EC 2.6.1.72: D-4-hydroxyphenylglycine transaminase EC 2.6.1.73: methionine—glyoxylate transaminase EC 2.6.1.74: cephalosporin-C transaminase EC 2.6.1.75: cysteine-conjugate transaminase EC 2.6.1.76: diaminobutyrate—2-oxoglutarate transaminase EC 2.6.1.77: taurine—pyruvate aminotransferase EC 2.6.1.78: aspartate—prephenate aminotransferase EC 2.6.1.79: glutamate—prephenate aminotransferase EC 2.6.1.80: nicotianamine aminotransferase EC 2.6.1.81: succinylornithine transaminase EC 2.6.1.82: putrescine aminotransferase EC 2.6.1.83: LL-diaminopimelate aminotransferase EC 2.6.1.84: arginine—pyruvate transaminase EC 2.6.1.85: aminodeoxychorismate synthase EC 2.6.1.86: 2-amino-4-deoxychorismate synthase EC 2.6.1.87: UDP-4-amino-4-deoxy-L-arabinose aminotransferase EC 2.6.1.88: methionine transaminase EC 2.6.1.89: dTDP-3-amino-3,6-dideoxy-α-D-glucopyranose transaminase EC 2.6.1.90: dTDP-3-amino-3,6-dideoxy-α-D-galactopyranose transaminase EC 2.6.1.91: Identical to EC 2.6.1.34, UDP-N-acetylbacillosamine transaminase EC 2.6.1.92: UDP-4-amino-4,6-dideoxy-N-acetyl-β-L-altrosamine transaminase EC 2.6.1.93: neamine transaminase EC 2.6.1.94: 2′-deamino-2′-hydroxyneamine transaminase EC 2.6.1.95: neomycin C transaminase EC 2.6.1.96: 4-aminobutyrate—pyruvate transaminase EC 2.6.1.97: archaeosine synthase EC 2.6.1.98: UDP-2-acetamido-2-deoxy-ribo-hexuluronate aminotransferase EC 2.6.1.99: L-tryptophan—pyruvate aminotransferase EC 2.6.1.100: L-glutamine:2-deoxy-scyllo-inosose aminotransferase EC 2.6.1.101: L-glutamine:3-amino-2,3-dideoxy-scyllo-inosose aminotransferase EC 2.6.1.102: GDP-perosamine synthase EC 2.6.1.103: (S)-3,5-dihydroxyphenylglycine transaminase EC 2.6.1.104: 3-dehydro-glucose-6-phosphate—glutamate transaminase EC 2.6.1.105: lysine—8-amino-7-oxononanoate transaminase EC 2.6.1.106: dTDP-3-amino-3,4,6-trideoxy-α-D-glucose transaminase EC 2.6.1.107: β-methylphenylalanine transaminase EC 2.6.1.108: (5-formylfuran-3-yl)methyl phosphate transaminase EC 2.6.1.109: 8-amino-3,8-dideoxy-α-D-manno-octulosonate transaminase EC 2.6.1.110: dTDP-4-dehydro-2,3,6-trideoxy-D-glucose 4-aminotransferase EC 2.6.1.111: 3-aminobutanoyl-CoA transaminase EC 2.6.1.112: (S)-ureidoglycine—glyoxylate transaminase EC 2.6.1.113: putrescine—pyruvate transaminase EC 2.6.1.114: 8-demethyl-8-aminoriboflavin-5′-phosphate synthase EC 2.6.1.115: 5-hydroxydodecatetraenal 1-aminotransferase EC 2.6.1.116: 6-aminohexanoate aminotransferase EC 2.6.1.117: L-glutamine—4-(methylsulfanyl)-2-oxobutanoate aminotransferase EC 2.6.1.118: [amino-group carrier protein]-γ-(L-lysyl)-L-glutamate aminotransferase EC 2.6.1.119: vanillin aminotransferase
Sources: en.wikipedia.org
不是。Semax 是完全人工合成的七肽，自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10)，但序列经过了替换和延长。
Semax 被描述为 ACTH(4-10) 的结构类似物，两者共享部分序列特征。它保留了该片段的部分神经相关活性方向，但去除了完整片段带来的激素释放效应。二者并非同一物质，也不能互相替代。
加入的 Pro-Gly-Pro 三肽被普遍认为能提升分子对蛋白水解酶的稳定性。这种设计让短肽在体内维持时间更长。具体延长的程度以及不同组织中是否一致，文献中仍存在不同报告。
Semax is a synthetic seven-amino-acid peptide derived from a fragment of corticotropin. It is used in Russia as a nasal preparation, while elsewhere it is studied as a research compound. It is not approved as a medicine in most countries.